Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

Interventions

DRUG: Ivosidenib 500mg
DRUG: Placebo

Sponsor

Servier Bio-Innovation LLC

Collaborators

[object Object]